- Home
- HNVR vs CNTB Comparison
HNVR vs CNTB Comparison
Compare HNVR & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNVR | CNTB |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.6M | 128.6M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HNVR | CNTB |
|---|---|---|
| Price | $21.34 | $2.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $24.50 | $8.50 |
| AVG Volume (30 Days) | 6.0K | ★ 103.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 75.22 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $26,033,000.00 |
| Revenue This Year | $28.03 | N/A |
| Revenue Next Year | $8.02 | $24,617.69 |
| P/E Ratio | $21.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.31 | $0.51 |
| 52 Week High | $24.36 | $3.28 |
Technical Indicators
Market Signals| Indicator | HNVR | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 53.95 |
| Support Level | $20.44 | $2.09 |
| Resistance Level | $22.53 | $2.86 |
| Average True Range (ATR) | 0.55 | 0.21 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 32.86 | 36.25 |
Price Performance
Historical ComparisonAbout HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.